Octreotide Acetate Patent Expiration
Octreotide Acetate was first introduced by Novartis Pharmaceuticals Corp
Octreotide Acetate Patents
Given below is the list of patents protecting Octreotide Acetate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Mycapssa | US11141457 | Oral octreotide therapy and contraceptive methods | Dec 28, 2040 | Chiesi |
Mycapssa | US11890316 | Oral octreotide therapy and contraceptive methods | Dec 28, 2040 | Chiesi |
Bynfezia Pen | US11052196 | Method of injecting octreotide acetate into the body | Nov 03, 2040 | Sun Pharm |
Bynfezia Pen | US11246991 | Electrolysis-resistant coupling assembly for valves | Nov 03, 2040 | Sun Pharm |
Bynfezia Pen | US11534553 | Method of injecting octreotide acetate into the body | Nov 03, 2040 | Sun Pharm |
Bynfezia Pen | US10342850 | Octreotide injection | May 15, 2038 | Sun Pharm |
Mycapssa | US10238709 | Method of treating diseases | Feb 03, 2036 | Chiesi |
Mycapssa | US10695397 | Method of treating diseases | Feb 03, 2036 | Chiesi |
Mycapssa | US11052126 | Method of treating diseases | Feb 03, 2036 | Chiesi |
Mycapssa | US11338011 | Method of treating diseases | Feb 03, 2036 | Chiesi |
Mycapssa | US11510963 | Method of treating diseases | Feb 03, 2036 | Chiesi |
Mycapssa | US11857595 | Method of treating diseases | Feb 03, 2036 | Chiesi |
Mycapssa | US11969471 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
Mycapssa | US11986529 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
Mycapssa | US8329198 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
Mycapssa | US8535695 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
Mycapssa | US9265812 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
Mycapssa | US9566246 | Pharmaceutical compositions and related methods of delivery | Sep 17, 2029 | Chiesi |
Sandostatin Lar |
US5922338 (Pediatric) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan 13, 2017
(Expired) | Novartis |
Sandostatin Lar |
US5922682 (Pediatric) | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jan 13, 2017
(Expired) | Novartis |
Sandostatin Lar | US5922338 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul 13, 2016
(Expired) | Novartis |
Sandostatin Lar | US5922682 | Polyol esters, their preparation and use in depot forms of pharmacologically active agents |
Jul 13, 2016
(Expired) | Novartis |
Sandostatin |
US5753618 (Pediatric) | Somatostatin analogue composition and use in treating breast cancer |
Nov 19, 2015
(Expired) | Novartis |
Sandostatin | US5753618 | Somatostatin analogue composition and use in treating breast cancer |
May 19, 2015
(Expired) | Novartis |
Sandostatin Lar |
US5688530 (Pediatric) | Sustained release formulations of water soluble peptides |
May 18, 2015
(Expired) | Novartis |
Sandostatin Lar |
US5639480 (Pediatric) | Sustained release formulations of water soluble peptides |
Dec 17, 2014
(Expired) | Novartis |
Sandostatin Lar | US5688530 | Sustained release formulations of water soluble peptides |
Nov 18, 2014
(Expired) | Novartis |
Sandostatin Lar | US5639480 | Sustained release formulations of water soluble peptides |
Jun 17, 2014
(Expired) | Novartis |
Sandostatin Lar |
US5538739 (Pediatric) | Sustained release formulations of water soluble peptides |
Jan 23, 2014
(Expired) | Novartis |
Sandostatin Lar | US5538739 | Sustained release formulations of water soluble peptides |
Jul 23, 2013
(Expired) | Novartis |
Octreotide Acetate's Family Patents
Explore Our Curated Drug Screens
Octreotide Acetate Generic API Manufacturers
Several generic applications have been filed for Octreotide Acetate. The first generic version for Octreotide Acetate was by West-Ward Pharmaceuticals International Ltd and was approved on Mar 28, 2005. And the latest generic version is by Hainan Shuangcheng Pharmaceuticals Co Ltd and was approved on May 2, 2024.
Given below is the list of companies who have filed for Octreotide Acetate generic, along with the locations of their manufacturing plants worldwide.
1. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 5 different strengths of generic version for Octreotide Acetate. Out of these eq 0.5mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE), eq 0.1mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE), eq 0.05mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE). Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.5MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2006 |
EQ 0.1MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2006 |
EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2006 |
EQ 1MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2006 |
EQ 0.2MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2006 |
Manufacturing Plant Locations New
Fresenius Kabi Usa's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Fresenius Kabi Usa as present at those locations.
Country | City | Firm Name | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
|
2. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 4 different strengths of generic version for Octreotide Acetate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.2MG BASE/ML | injectable | Prescription | INJECTION | AP | Jun 13, 2023 |
EQ 1MG BASE/ML | injectable | Prescription | INJECTION | AP | Jun 13, 2023 |
EQ 0.5MG BASE/ML | injectable | Prescription | INJECTION | AP | Jun 22, 2023 |
EQ 0.1MG BASE/ML | injectable | Prescription | INJECTION | AP | Jun 22, 2023 |
3. HERITAGE
Heritage Pharmaceuticals Inc Dba Avet Pharmaceuticals Inc has filed for 5 different strengths of generic version for Octreotide Acetate. Given below are the details of the strengths of this generic introduced by Heritage.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 1MG BASE/ML | injectable | Prescription | INJECTION | AP | Sep 7, 2018 |
EQ 0.2MG BASE/ML | injectable | Prescription | INJECTION | AP | Sep 7, 2018 |
EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Dec 27, 2018 |
EQ 0.1MG BASE/ML | injectable | Prescription | INJECTION | AP | Dec 27, 2018 |
EQ 0.5MG BASE/ML | injectable | Prescription | INJECTION | AP | Dec 27, 2018 |
Manufacturing Plant Locations New
Heritage's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Heritage as present at those locations.
Country | City | Firm Name | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United States |
|
4. MEITHEAL
Meitheal Pharmaceuticals Inc has filed for 5 different strengths of generic version for Octreotide Acetate. Given below are the details of the strengths of this generic introduced by Meitheal.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.5MG BASE/ML | injectable | Prescription | INJECTION | AP | Oct 3, 2005 |
EQ 0.1MG BASE/ML | injectable | Prescription | INJECTION | AP | Oct 3, 2005 |
EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Oct 3, 2005 |
EQ 0.2MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 21, 2005 |
EQ 1MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 21, 2005 |
5. MYLAN INSTITUTIONAL
Mylan Institutional Llc has filed for 3 different strengths of generic version for Octreotide Acetate. All of these versions come by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE). Given below are the details of the strengths of this generic introduced by Mylan Institutional.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2011 |
EQ 0.1MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2011 |
EQ 0.5MG BASE/ML | injectable | Prescription | INJECTION | AP | Feb 10, 2011 |
Manufacturing Plant Locations New
Mylan Institutional's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Mylan Institutional as present at those locations.
Country | City | Firm Name | ||
---|---|---|---|---|
United States |
|
6. SAGENT PHARMS INC
Sagent Pharmaceuticals Inc has filed for 5 different strengths of generic version for Octreotide Acetate. Out of these eq 0.05mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE), eq 0.1mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE), eq 0.5mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE). Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.2MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 12, 2013 |
EQ 0.05MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 12, 2013 |
EQ 0.1MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 12, 2013 |
EQ 0.5MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 12, 2013 |
EQ 1MG BASE/ML | injectable | Prescription | INJECTION | AP | Nov 12, 2013 |
7. SHUANGCHENG
Hainan Shuangcheng Pharmaceuticals Co Ltd has filed for 1 generic for Octreotide Acetate. Given below are the details of the strengths of this generic introduced by Shuangcheng.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.1MG BASE/ML | injectable | Discontinued | INJECTION | N/A | May 2, 2024 |
8. SUN PHARM INDS
Sun Pharmaceutical Industries Ltd has filed for 5 different strengths of generic version for Octreotide Acetate. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.05MG BASE/ML | injectable | Discontinued | INJECTION | N/A | Mar 4, 2008 |
EQ 0.1MG BASE/ML | injectable | Discontinued | INJECTION | N/A | Mar 4, 2008 |
EQ 0.5MG BASE/ML | injectable | Discontinued | INJECTION | N/A | Mar 4, 2008 |
EQ 0.2MG BASE/ML | injectable | Discontinued | INJECTION | N/A | Mar 4, 2008 |
EQ 1MG BASE/ML | injectable | Discontinued | INJECTION | N/A | Mar 4, 2008 |
9. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Octreotide Acetate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 20MG BASE/VIAL | injectable | Prescription | INJECTION | AB | Dec 5, 2023 |
EQ 10MG BASE/VIAL | injectable | Prescription | INJECTION | AB | Dec 5, 2023 |
EQ 30MG BASE/VIAL | injectable | Prescription | INJECTION | AB | Dec 5, 2023 |
10. WEST-WARD PHARMS INT
West-ward Pharmaceuticals International Ltd has filed for 5 different strengths of generic version for Octreotide Acetate. Out of these eq 0.1mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE), eq 0.5mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE), eq 0.05mg base/ml version comes by the name OCTREOTIDE ACETATE (PRESERVATIVE FREE). Given below are the details of the strengths of this generic introduced by West-ward Pharms Int.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.1MG BASE/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Mar 28, 2005 |
EQ 0.5MG BASE/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Mar 28, 2005 |
EQ 0.05MG BASE/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Mar 28, 2005 |
EQ 0.2MG BASE/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Apr 8, 2005 |
EQ 1MG BASE/ML
(reference standard) | injectable | Prescription | INJECTION | AP | Apr 8, 2005 |
11. WOCKHARDT USA
Wockhardt Usa Inc has filed for 5 different strengths of generic version for Octreotide Acetate. Out of these eq 0.1mg base/ml version comes by the name OCTREOTIDE ACETATE PRESERVATIVE FREE, eq 0.05mg base/ml version comes by the name OCTREOTIDE ACETATE PRESERVATIVE FREE, eq 0.5mg base/ml version comes by the name OCTREOTIDE ACETATE PRESERVATIVE FREE. Given below are the details of the strengths of this generic introduced by Wockhardt Usa.
Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
---|---|---|---|---|---|
EQ 0.1MG BASE/ML | injectable | Discontinued | INJECTION | N/A | May 11, 2011 |
EQ 0.2MG BASE/ML | injectable | Discontinued | INJECTION | N/A | May 11, 2011 |
EQ 1MG BASE/ML | injectable | Discontinued | INJECTION | N/A | May 11, 2011 |
EQ 0.05MG BASE/ML | injectable | Discontinued | INJECTION | N/A | May 11, 2011 |
EQ 0.5MG BASE/ML | injectable | Discontinued | INJECTION | N/A | May 11, 2011 |